GleamWall
中文EN

STIM Neuronetics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1227636 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY23.0%
TTM net income YoY48.1%
TTM EPS YoY61.4%
Revenue 3-yr CAGR32.1%
Net income 3-yr CAGR—

Margins

Gross margin50.7%
Operating margin-9.4%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-8.0%

Returns

ROE-100.2%
ROA-16.6%
ROIC (approx.)-19.2%
Asset turnover1.15x

Leverage & solvency

Liabilities / assets83.0%
Debt / equity3.30x
Current ratio2.01x
Interest coverage-1.69x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-10.7%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$149.16M$74.89M$71.35M$65.21M$55.31M
Cost of revenue$76.85M$20.73M$19.64M$15.48M$11.65M
Gross profit$72.31M$54.16M$51.70M$49.72M$43.66M
R&D expense$6.58M$12.77M$9.52M$9.34M$7.92M
SG&A expense$49.70M$30.32M$25.43M$25.52M$25.55M
Operating income-$31.44M-$34.56M-$30.55M-$35.11M-$27.56M
Interest expense$8.41M$7.29M$5.42M$4.25M$4.02M
Net income-$39.00M-$43.71M-$30.19M-$37.16M-$31.19M
EBITDA-$27.97M-$32.49M-$28.55M-$33.46M-$26.50M
EPS (basic)-0.59-1.38-1.05-1.38-1.22
EPS (diluted)-0.59-1.38-1.05-1.38-1.22
Weighted avg. shares (diluted)65.95M31.73M28.66M26.90M25.48M
Balance sheet
Cash & equivalents$28.13M$19.46M$59.68M$70.34M$94.14M
Receivables$16.47M$23.36M$15.78M$13.59M$7.71M
Inventory$4.33M$4.25M$8.09M$8.90M$6.56M
Current assets$61.55M$58.12M$93.79M$98.77M$115.33M
PP&E, net$4.47M$6.24M$2.01M$1.99M$1.22M
Goodwill$23.62M$18.63M———
Intangibles$18.15M$19.61M———
Total assets$141.55M$140.90M$115.83M$116.88M$141.22M
Current liabilities$30.52M$31.27M$19.81M$33.20M$15.70M
Short-term debt———$13.12M—
Long-term debt$65.81M$55.15M$59.28M$22.83M$35.34M
Total debt$65.81M$55.15M$59.28M$35.95M$35.34M
Total liabilities$115.31M$109.10M$81.64M$59.82M$56.05M
Shareholders' equity$22.38M$27.71M$34.19M$57.06M$85.17M
Net debt$37.67M$35.69M-$394,000-$34.39M-$58.81M
Shares outstanding68.99M55.68M29.09M27.27M26.39M
Cash flow statement
Operating cash flow-$20.37M-$31.00M-$32.04M-$30.74M-$27.98M
Capital expenditure$801,000$1.47M$2.37M$3.27M$2.35M
Free cash flow-$21.18M-$32.46M-$34.41M-$34.01M-$30.34M
Investing cash flow-$801,000-$2.41M-$1.32M$6.73M-$9.84M
Financing cash flow$35.85M-$6.81M$22.70M$207,000$83.01M
Depreciation & amortization$3.46M$2.07M$2.01M$1.65M$1.06M
Stock-based compensation$6.85M$5.60M$7.32M$8.75M$7.87M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.